Pharmacotherapy · 2002
Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Einhorn Allison E, Neuhauser Melinda M, Bearden David T, Quinn John P, Pendland Susan L
Аннотация
STUDY OBJECTIVE: To determine epidemiologic factors of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in a nonoutbreak setting.
DESIGN: Retrospective analysis.
SETTING: University teaching hospital.
PATIENTS: Fifty-seven patients with cultures of presumed ESBL-producing (i.e., ceftazidime-resistant) E. coli or K. pneumoniae.
INTERVENTIONS: To determine overall frequency, institutional antibiograms from 1991-1999 were examined for percentage of isolates with ceftazidime resistance. Medical records from January 1997-June 2000 were reviewed for patient demographics, comorbidities, culture site, antimicrobial therapy, and clinical and microbiologic outcomes.
MEASUREMENTS AND MAIN RESULTS: From 1991-1999, frequency increased from undetectable to 4% for ceftazidime-resistant E. coli and from 2% to 6% for ceftazidime-resistant K. pneumoniae. Seventy-one isolates were identified in the 57 patients with presumed ESBL-producing E. coli or K. pneumonia. Fifty-one isolates (72%) were E. coli, with urine the primary site of infection (62%). Eighty-six percent of patients had known risk factors for infection due to ESBL-producing organisms, including hospitalization (37 patients) and residence in long-term care facilities (12 patients). However, in 14% (8 patients), the infection was community acquired in patients who resided at home.
CONCLUSION: In addition to known populations at risk, ambulatory patients with chronic conditions represent another patient population that may harbor ESBL-producing organisms.
DESIGN: Retrospective analysis.
SETTING: University teaching hospital.
PATIENTS: Fifty-seven patients with cultures of presumed ESBL-producing (i.e., ceftazidime-resistant) E. coli or K. pneumoniae.
INTERVENTIONS: To determine overall frequency, institutional antibiograms from 1991-1999 were examined for percentage of isolates with ceftazidime resistance. Medical records from January 1997-June 2000 were reviewed for patient demographics, comorbidities, culture site, antimicrobial therapy, and clinical and microbiologic outcomes.
MEASUREMENTS AND MAIN RESULTS: From 1991-1999, frequency increased from undetectable to 4% for ceftazidime-resistant E. coli and from 2% to 6% for ceftazidime-resistant K. pneumoniae. Seventy-one isolates were identified in the 57 patients with presumed ESBL-producing E. coli or K. pneumonia. Fifty-one isolates (72%) were E. coli, with urine the primary site of infection (62%). Eighty-six percent of patients had known risk factors for infection due to ESBL-producing organisms, including hospitalization (37 patients) and residence in long-term care facilities (12 patients). However, in 14% (8 patients), the infection was community acquired in patients who resided at home.
CONCLUSION: In addition to known populations at risk, ambulatory patients with chronic conditions represent another patient population that may harbor ESBL-producing organisms.